Skip to main content
OpenTrials
Completed

NCT Number: NCT03565835

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used to treat patients with prostate cancer. When abiraterone and prednisone are used, hormone injections are usually continued to maintain a low testosterone level in the blood. This study is being done to find out if testosterone in the blood will stay low while abiraterone and prednisone are used without continued hormone injections.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostatic Neoplasms Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

Montefiore Medical Center

The Bronx, New York, 10461, United States

About this study

Abiraterone inhibits the CYP17A enzyme, which is a critical enzyme in androgen biosynthesis. Abiraterone has regulatory approval in metastatic castration-resistant prostate cancer (mCRPC) in both chemotherapy-naïve and in the post-docetaxel setting based upon results from two randomized phase III studies. Abiraterone is also proven to extend survival in the metastatic, hormone-naïve population based on two phase III studies. Abiraterone is a castrating agent, but, other than a small first in human study, all clinical studies have been done in conjunction with gonadotropin-releasing hormone (GnRH) analogues. Maintaining castrate level of serum testosterone is critical in the treatment of metastatic prostate cancer. It is unknown if GnRH analogues must be continued to maintain castrate levels of serum testosterone in patients treated with abiraterone.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient must be able to provide study-specific informed consent prior to study entry
  • Age ≥ 18
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
  • Pathologically proven diagnosis of prostate adenocarcinoma
  • Patients must have metastatic prostate cancer
  • Patients may have mCRPC or may have metastatic castration-sensitive disease.
  • Patients must be maintained on a GnRH analogue (agonist (leuprolide, goserelin, triptorelin, histrelin, deslorelin) or antagonist (degarelix))
  • The patient and the investigator have decided that the next line of cancer therapy will be abiraterone plus prednisone and the initial dose of abiraterone will be 1000 mg daily. Or patients may already be on abiraterone with prednisone at a dose of 1000 mg daily along with a GnRH analogue.
  • Lab values meeting the following criteria
  • Total testosterone level of <50 ng/dl
  • Total bilirubin < 2.0 X Upper Limit of Normal (ULN)
  • Aspartate aminotransferase (AST) ≤ 3 X ULN
  • Alanine aminotransferase (ALT) ≤ 3 X ULN
  • Absolute Neutrophil Count > 1.5 K/mm3
  • Platelets > 100 K/mm3
  • Hemoglobin ≥ 9.0 g/dL
  • Calculated creatinine clearance ≥ 30 mL/min

Exclusion criteria

  • History of bilateral orchiectomy
  • History of hypopituitarism
  • For patients not yet started on abiraterone with prednisone, uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >100 mm Hg)
  • Patients must not have New York Heart Association Class III or IV heart failure at the time of screening. Patients must not have any unstable angina, myocardial infarction, or serious uncontrolled cardiac arrhythmia within 6 months prior to registration
  • Any other serious illness or medical condition that the principal investigator feels would make the patient a poor candidate for this study

Treatment and study plan

Abiraterone Acetate

Drug

Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue

Prednisone

Drug

Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue

Primary outcomes

  1. Percentage of Patients With Castrate Level of Serum Testosterone

    Time frame: Approximately 24 weeks

    The number/percentage of patients with a castrate serum testosterone level, defined as having a serum castrate concentration <50 ng/dL when Abiraterone acetate plus prednisone (AAP) is used without GnRH analogues in metastatic prostate cancer, will be determined. Results are summarized as a number/percentage of participants.

Secondary outcomes

  1. Serum Testosterone (T) Levels

    Time frame: Baseline and 6 months, 12 months, 18 months, 24 months, and 30 months following initiation of treatment

    Mean serum testosterone (T) concentrations in patients with metastatic prostate cancer treated with abiraterone acetate plus prednisone without a GnRH analogue was measured. Results have been summarized and reported in nanograms/deciliter (ng/dL) using basic descriptive statistics.

  2. Serum Luteinizing Hormone (LH) Levels

    Time frame: Baseline and 6 months, 12 months, 18 months, 24 months, and 30 months following initiation of treatment

    Mean serum LH levels in patients with metastatic prostate cancer treated with abiraterone acetate plus prednisone without a GnRH analogue was measured. Results have been summarized and reported in International Units/Liter (IU/L) using basic descriptive statistics.

  3. Prostate-specific Antigen (PSA) Response

    Time frame: Baseline and 6 months, 12 months, 18 months, 24 months, and 30 months following initiation of treatment

    Mean PSA response in patients with metastatic prostate cancer treated with abiraterone acetate plus prednisone without a GnRH analogue was measured. Results have been summarized and reported in ng/mL using basic descriptive statistics.

  4. Treatment-related Adverse Events Due to Toxicity

    Time frame: 24 weeks

    The number of patients with treatment-related adverse events due to toxicity which lead to discontinuation from the study at 24 weeks is summarized.

  5. Radiographic Progression-free Survival (rPFS)

    Time frame: From initiation of treatment to the end of treatment, up to approximately 41 months (~178 weeks)

    The duration of time from trial entry until radiographic progression-free survival will be measured/reported. Progression-free survival is an assessment of the average time a patient lives without disease progression, as detected on radiographic imaging scans, or the patient dies from the disease, whichever comes first. Results have been summarized and reported in weeks using basic descriptive statistics.

  6. Overall Survival (OS)

    Time frame: From initiation of treatment until the end of treatment, up to approximately 41 months

    Overall survival is an assessment of survival from the time initiation of treatment until the time of death to death due to any cause. Results have been summarized and reported in weeks using basic descriptive statistics.

Sponsors and collaborators

Lead sponsor

Montefiore Medical Center

Other

Registry information

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jun 21, 2018
Registry last updated
Jan 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.